### Vaginal Ring

**Dapivirine Ring**

- **Efficacy Trial**
- **Status:** Ongoing in 2,700 MSM and transgender men & women in Brazil, Peru, Switzerland, US.

### Antibody

**VRC01**

- **Efficacy Trial**
- **Status:** Randomized controlled trial of the VRC01 antibody infused every two months; ongoing in 2,700 MSM and transgender men & women in Brazil, Peru, Switzerland, US.

### Oral PrEP

**DISCOVER (Daily pill)**

- **Efficacy Trial**
- **Status:** FDA approval for adults and adolescents who do not have receptive vaginal sex.
- **Research planned to gather data needed for people excluded from the current FDA indication**

**MK-8591 (Monthly pill)**

- **Efficacy Trial**
- **Status:** Randomized controlled trial of islatravir; ongoing in 250 men and women in Israel, South Africa, US.

### Long-Acting Injectable

**Cabotegravir**

- **Efficacy Trial**
- **Status:** Randomized controlled trial of injectable cabotegravir every two months; ongoing in 4,500 MSM and transgender women in Argentina, Brazil, Peru, South Africa, Thailand, US, Vietnam.

- **Status:** May 2020: Blinded, randomized portion of the trial stopped early for efficacy. Participants in both arms of the study will be offered CAB LA.

- **Status:** November 2020: Blinded, randomized portion of the trial stopped early for efficacy. Participants in both arms of the study will be offered CAB LA.

### Preventive HIV Vaccine

**ALVAC/gp120 w/MF59**

- **Efficacy Trial**
- **Status:** Randomized controlled trial of ALVAC/gp120 prime-boost with MF59 adjuvant, six doses over 18 months; 5,400 men and women in South Africa; immunizations halted for non-efficacy; follow-up ongoing.

**Ad26/gp140 boost**

- **Efficacy Trial**
- **Status:** Randomized controlled trial of Ad26 prime with gp140 boost; four doses over 12 months; ongoing in 2,600 women in Malawi, Mozambique, South Africa, Zambia, Zimbabwe.

**Ad26/clade C gp140 & mosaic gp140 boost**

- **Efficacy Trial**
- **Status:** Randomized controlled trial of Ad26 prime with clade C and mosaic gp140 boost; ongoing in 3,800 MSM and transgender people in Argentina, Brazil, Italy, Mexico, Peru, Poland, Spain, US.

### PrEP and vaccine

**PrEPVacc**

- **Efficacy Trial**
- **Status:** Randomized controlled trial of DNA-MVA-env or DNA-env with F/TAF or F/TDF; planned in 1668 participants in Mozambique, South Africa, Tanzania, Uganda.

---

**Footnotes:**

- *Ongoing*
- *Planned* *Phase IIa trial*